ArticleFrontiers in cardiovascular medicine2024

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

V Quagliariello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.